Product

ATRIPLA^TM

Name

Atripla

INN Name

efavirenz, emtricitabine, and tenofovir disoproxil fumarate

FDA Approved

Yes

1 clinical trial

1 organization

2 indications

1 document

Indication

Indication

Central Nervous System

Clinical trial

Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.

Status: Completed, Estimated PCD: 2018-08-14

Document

DailyMed Label: Atripla

Organization

Gilead Sciences, LLC